Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

26.79 +0.35 (+1.32%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist

Price and Volume

Volume	462,131
Open	26.27
Bid (Size)	26.79 (200)
Ask (Size)	26.80 (2,700)
Prev. Close	26.44
Today's Range	26.02 - 26.82
52wk Range	14.40 - 29.05
Shares Outstanding	66,344,236
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗

November 10, 2025

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...

Via Benzinga

Performance

YTD	+3.9%	+3.9%
1 Month	-2.1%	-2.1%
3 Month	+18.5%	+18.5%
6 Month	+43.6%	+43.6%
1 Year	+0.1%	+0.1%

More News

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

November 10, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Upcoming Investor Conferences

November 07, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

November 06, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients

November 06, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

October 30, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Analyst Expectations For Celldex Therapeutics's Future ↗

October 13, 2025

Via Benzinga

Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗

October 03, 2025

Via Chartmill

5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗

September 17, 2025

Via Benzinga

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

September 17, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

September 09, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 08, 2025

Via Benzinga

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗

August 20, 2025

Via Benzinga

What Analysts Are Saying About Celldex Therapeutics Stock ↗

August 20, 2025

Via Benzinga

La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

August 20, 2025

Via Benzinga

Why Are Celldex Shares Tumbling After Hours? ↗

August 19, 2025

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

August 19, 2025

Via Chartmill

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

August 19, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2025

Via Benzinga

Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress ↗

August 07, 2025

Via Chartmill

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 07, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?

Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?

Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?

The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market

What is the current price of Celldex Therapeutics, Inc. - Common Stock?

The current price of Celldex Therapeutics, Inc. - Common Stock is 26.79

When was Celldex Therapeutics, Inc. - Common Stock last traded?

The last trade of Celldex Therapeutics, Inc. - Common Stock was at 11/26/25 04:00 PM ET

What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?

The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.78B

How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?

Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.